Therapie mit dabigatran: Periinterventionelles management und interpretation von gerinnungstests

Hamostaseologie

Volumn 32, Issue 4, 2012, Pages 294-305

  Spannagl, M ^a   Bauersachs, R ^b   Debus, E S ^c   Gawaz, M ^d   Gerlach, H ^e   Haas, S ^f   Hach Wunderle, V ^g   Lindhoff Last, E ^h   Riess, H ⁱ   Schellong, S ^j   Schinzel, H ^k   Bode, C ^l  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Department of Angiology   (Germany)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e Berufsverband der Phlebologen e V Mannheim   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g Venenzentrum Frankfurt am Main   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^k UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^l UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

more..

Author keywords

Activated partial thromboplastin time; aPPT; Atrial fibrillation; Dabigatran; Dabigatran etexilate; Diluted thrombin time; Ecarin clotting time; ECT; Hemoclot; Perioperative management; Stroke prevention; Thrombin time; Thrombosis prophylaxis; TT

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE; PROTHROMBIN COMPLEX; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG BLOOD LEVEL; ELECTIVE SURGERY; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMODYNAMICS; HIGH RISK PATIENT; HIP ARTHROPLASTY; HUMAN; KIDNEY FUNCTION; KNEE ARTHROPLASTY; THROMBIN TIME; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING TEST; CHEMICALLY INDUCED DISORDER; METHODOLOGY; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION TESTS; HUMANS; MONITORING, INTRAOPERATIVE; POSTOPERATIVE HEMORRHAGE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84873589886     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-2012030004     Document Type: Article

References (34)

1. Fachinformation Pradaxa 75 mg und 110 mg Hartkapseln. Juni 2012. Boehringer Ingelheim.
2. Fachinformation Pradaxa 110 mg und 150 mg Hartkapseln. Juni 2012. Boehringer Ingelheim.
3. Van Ryn J, Strangier J, Haertter S et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
4. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
5. Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
6. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
7. Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
8. Eriksson BI, Dahl OE, Huo MH et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-729.
9. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
10. Schulman S, Baanstra D, Eriksson H et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011; 9: O-Mo-037.
11. Schulman S, Eriksson H, Goldhaber SZ et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011; 9: O-Thu-033.
12. Healey JS, Eikelboom J, Douketis J et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial. Circulation 2012; 126: 343-348.
13. Huisman MV, Lip GY, Diener HC et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost 2012; 107; 838-847.
14. Steiner T, Dichgans M, Diener HC et al. Handlungsempfehlungen zum Notfallmanagement bei Dabigatran assoziierten Akut-Komplikationen. DIVI 2012; 3: 10-16.
15. Warkentin TE, Margetts P, Connolly SJ et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174.
16. Van Ryn J, Ruehl D, Priepke H et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor, dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. 13th Congress of the European Hematology Association, Copenhagen, Denmark, June 12-15 2008: 148.
17. Van Ryn J, Dörr B, Kaspereit F et al. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits. 21st International Congress on Thrombosis, Milan, Italy, July 6-9 2010: A94.
18. Van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. ASH Annual Meeting Abstracts 2011 Nov 18; 118: 2316.
19. Zhou W, Schwarting S, Illanes S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
20. Liesenfeld KH, Lehr T, Dansirikul C et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9: 2168-2175.
21. Mueck W, Lensing AW, Agnelli G et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
22. Stangier J, Rathgen K, Stahle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
23. Liesenfeld KH, Schafer HG, Troconiz IF et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527-537.
24. Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-1426.
25. Weltermann A, Brodmann M, Domanovits H et al. Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. Wien Klin Wochenschr 2012; 124: 340-347.
26. Van Ryn J, Baruch L, Clemens A. Interpretation of © Schattauer 2012 Hämostaseologie 4/2012 M. Spannagl et al.: Dabigatran 305 Point-of-care INR results in patients treated with dabigatran. Am J Med 2012; 125: 417-420.
27. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
28. Wagner F, Peters H, Formella, Wiegert E et al. Effective elimination of dabigatran with haemodialysis: A phase I single-centre study in patients with end stage renal disease. Amercian Heart Association Scientific Session 2011, Orlando Florida 13-15 November: 4-11-2011.
29. Wanek MR, Horn ET, Elapavaluru S et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012; 46: e21.
30. PHARMAC New Zealand Government. Guidelines for management of bleeding with dabigatran - for possible inclusion into local management protocols. 2011.
31. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
32. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
33. Lehr T, Haertter S, Liesenfeld KH et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: Dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012; 52: 1373-1378.
34. Hohnloser SH, Diener HC. Dabigatran for stroke prevention in atrial fibrillation. Hämostaseologie 2012; 32: 216-220.